财报数据
| EPS 实际 | $1.15 |
| EPS 预期 | $1.1552 |
| EPS 超预期 % | -0.45% |
| 收入实际 | $11,164,000,000 |
| 收入预期 | $11,107,537,135 |
| 判据命中 | 新闻 B |
观察状态
| 状态 | 🟢 已收尾 |
| Time0（观察起点） | 2026-04-16 16:24:00 UTC （盘中） |
| 基准价 P₀ | $95.89 |
| 累计最高价 | $96.00 |
| 峰值涨幅 | +0.12% |
| Time1（回撤触发） | 2026-04-16 16:39:00 UTC |
| Time1 价格 | $95.09 |
| 最终涨幅 | -0.83% |
分钟级价格（Massive 数据） 绿线 = Time0 发生时刻 · 红线 = Time1 回撤触发时刻
加载中…
触发新闻（1 条）
按发布时间升序；最早一篇的 published_utc 即为 Time0
2026-04-16 16:24:42 UTC
· Benzinga
·
✓ LLM 判定为 beat
（置信 0.98）
Abbott Laboratories beat Q1 earnings expectations with $11.16B in sales and $1.15 EPS, driven by strong Medical Devices and Diabetes Care growth. However, the company cut its 2026 full-year earnings g…
└ LLM 理由: The article explicitly says Abbott Laboratories beat Q1 earnings expectations, reporting $11.16B in sales and $1.15 EPS. Although lowered guidance hurt the stock, the just-reported quarter exceeded a